从hPSCs生成双属性iTNK细胞,用于癌症免疫治疗
Yingfeng Zhang1, Yuanyuan He1, Chenyi Dai2
1Peking-Tsinghua Center for Life Sciences, The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
Cell reports methods
|August 31, 2024
概括
人类多能干细胞 (hPSC) 是双属性免疫细胞的有希望的来源,结合了细胞毒性T和自然杀手 (NK) 细胞功能,用于高级癌症免疫治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 干细胞生物学 干细胞生物学
- 癌症研究 癌症研究
背景情况:
- 双属性免疫细胞融合了细胞毒性T细胞和自然杀手 (NK) 细胞的特性,在免疫治疗中显示出治疗潜力.
- 现有的双属性细胞类型,如iNKT和CIK细胞已经显示出有效性,但在可用性方面面临限制.
- 人类多能干细胞 (hPSC) 是产生这些先进免疫细胞的可行和可扩展的来源.
研究的目的:
- 从hPSCs产生双属性诱导的T-NK (iTNK) 细胞.
- 描述hPSC衍生的iTNK细胞的免疫细胞标记物和T细胞受体 (TCR) 谱.
- 评估这些iTNK细胞的细胞毒性潜力和体内抗瘤功效.
主要方法:
- 从hPSCs生成iTNK细胞.
- 单细胞RNA和TCR测序用于全面的细胞分析.
- 在实验室中对各种瘤细胞系进行细胞毒性检测.
- 在体内瘤生长抑制研究.
主要成果:
- 由hPSC衍生的iTNK细胞表达T细胞和NK细胞特有的标记物.
- 单细胞分析证实了关键基因的表达和多样化的TCR谱.
- iTNK细胞对瘤细胞表现出强大的细胞毒性,并在体内抑制了瘤生长.
- 这些细胞有效地利用了适应性和先天性免疫反应.
结论:
- 来自hPSC的iTNK细胞代表了癌症免疫疗法的新且有前途的细胞来源.
- 这些细胞结合了T细胞和NK细胞的优势,增强了抗瘤活性.
- 这种方法提供了一个可扩展的策略,以克服当前双属性免疫细胞疗法的局限性.
相关概念视频
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K


